newsfilter
← Latest News
GlobeNewswire·

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

DXR
  • Daxor Corporation provided a mid-year corporate and financial update for the six months ended June 30, 2026, emphasizing strategic preparations for aggressive growth.
  • The company completed a $9 million gross capital raise in January 2026 to strengthen its foundation, eliminate short-term debt, expand manufacturing capacity, and stock inventory.
  • Unaudited kit sales grew 16% in the first half of 2026, driven by legacy commercial structures before new sales leadership began expanding the team.
  • Annette Plishka was appointed SVP of Sales in April 2026, with plans to expand the sales and clinical support team by 300% over the coming quarters.
  • New account activity included a BVA program launch in Southern Tennessee in February and a high-volume cardiology center in Southwest Ohio in April.
  • Daxor received indications of interest from more than fifteen hospitals and practices for its next-generation BVA system, which received FDA 510(k) clearance in August 2025.
  • Net assets increased to $51,832,130 as of June 30, 2026, with a Net Asset Value (NAV) per share of $8.88, reflecting a debt-free balance sheet.
  • The company retired $1,169,913 of short-term debt using proceeds from the January capital raise, leaving no outstanding debt or derivative securities.
  • Operating investments focused on upgrading the Oak Ridge facility to increase radiopharmaceutical kit output capacity by over 500%, purchasing tooling for the next-generation analyzer, and building inventory.
  • Daxor is transitioning primary regulatory reporting from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, though the Commission has not yet acted on the application.
  • The company sold its remaining investment portfolio in December 2025 and currently holds no common or preferred stock positions.
  • The USPTO issued U.S. Patent No. 12,635,917 B2 on June 2, 2026, for a "Remote Blood Volume Monitor" to enable continuous, wearable-sensor-based monitoring.
  • Clinical data presented at conferences in March 2026 showed BVA-guided care associated with a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality.
  • Recent developments include a new outpatient BVA program launch in eastern Kansas in July and an exhibition at the Dysautonomia International Conference to explore autonomic disorder indications.